ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2895

Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis

Seunghun Lee1, Sung Won Lee2, Yoonah Song1, Il-Hoon Sung3 and Tae-Hwan Kim2, 1Department of Radiology, Hanyang University College of Medicine, Seoul Hospital, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Department of Orthopaedic Surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS) and glucocorticoids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease which involves axial skeleton. NSAIDs are drug of choice and biologic disease-modifying anti-rheumatic drugs (DMARDs) are strongly recommended in case of NSAIDs failure. But some AS patients have intermittent, migratoy pain and inflammatory pain could last several days or weeks. Intraarticular injections of sacroiliac joints are recommended in these cases.

The goal of this study was to analyze the effectiveness of a fluoroscopy-guided intraarticular corticosteroid injection for the treatment of sacroiliac joint pain in patients with AS.

Methods: Between March 2012 and February 2015, a total of 62 fluoroscopy-guided intraarticular corticosteroid injections in the sacroiliac joints were performed in 58 patients with AS (37 males, 21 females; mean age 29.1 years, range 12 to 66 years). All patients had been previously diagnosed with AS according to the modified New York criteria And there were findings of active inflammation in their sacroiliac joints confirmed by pelvic magnetic resonance imaging (MRI).

The mixture of triamcinolone acetonide 40 mg and normal saline 0.5 mL was injected under floroscopic guidance.

Results: The mean disease duration before injection was 26.7 months (range 0 to 151 months) and the mean follow-up after injection was 15.1 months (range 0 to 35 months). After injection, BASDAI score and levels of acute phase reactant were decreased. The mean BASDAI score before injection was 6.26 (range 2.3 to 10.0) and the mean BASDAI score after injection was 4.81 (range 1.0 to 9.2). BASDAI 50%/20mm response rate was 27.4% (17/62). In 24 out of 62 cases (39.0%), the BASDAI score were below 4 which means optimal control of disease. No initiation of biologic DMARDs and additional intervention was required in 39 out of 54 patients (72.2%).

But 4 out of 58 patients (6.9%) needed a second injection. 3 patients already was on biologic DMARDs before injection, 15 patients newly started biologic DMRADs after injection due to their high disease activity and lack of effectiveness of intraarticular injection. There were neither discontinuity nor change of biologic DMARDs. There was no bilateral injection at once and no complication associated with the procedure. There was no significant difference between dose of medications which is prescribed before and after injection.

Conclusion: Fluoroscopy-guided corticosteroid injection into sacroiliac joint could be considered as one of treatment options instead of starting biologic DMARDs or dose escalation of medications, when AS patients complain of abrupt and severe pain in their sacroiliac joints.


Disclosure: S. Lee, None; S. W. Lee, None; Y. Song, None; I. H. Sung, None; T. H. Kim, None.

To cite this abstract in AMA style:

Lee S, Lee SW, Song Y, Sung IH, Kim TH. Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/intraarticular-sacroiliac-corticosteroid-injections-in-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intraarticular-sacroiliac-corticosteroid-injections-in-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology